| GRP/GRPR enhances alcohol-associated liver injury through the IRF1-mediated Caspase-1 inflammasome and NOX2-dependent ROS pathway. | GRP/GRPR enhances alcohol-associated liver injury through the IRF1-mediated Caspase-1 inflammasome and NOX2-dependent ROS pathway.
Li H, Chen X, Xu J, Zhu L, Li C, Sun X, Li X, Guo J, Li J, Wang S, He Y, Wang H, Huang C, Meng XM, Li J. | 01/26/2024 |
| Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer. | Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
Li L, Zhang Q, Wang Y, Xu C., Free PMC Article | 06/1/2023 |
| Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma. | Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma.
Giovanella L, Fontana M, Keller F, Campenni' A, Ceriani L, Paone G. | 03/19/2022 |
| Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer. | Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer.
Yu M, Yang C, Wang S, Zeng Y, Chen Z, Feng N, Ning C, Wang L, Xue L, Zhang Z. | 08/14/2021 |
| Gastrin-releasing peptide induces fibrotic response in MRC5s and proliferation in A549s. | Gastrin-releasing peptide induces fibrotic response in MRC5s and proliferation in A549s.
Kayalar O, Oztay F, Ongen HG., Free PMC Article | 08/14/2021 |
| Expression and clinical value of gastrin-releasing peptide precursor in nephropathy and chronic kidney disease. | Expression and clinical value of gastrin-releasing peptide precursor in nephropathy and chronic kidney disease.
Dai Z, Zhu J, Huang H, Fang L, Lin Y, Huang S, Xie F, Sheng N, Liang X. | 02/2/2021 |
| The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. | The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients.
You B, Mercier F, Assenat E, Langlois-Jacques C, Glehen O, Soulé J, Payen L, Kepenekian V, Dupuy M, Belouin F, Morency E, Saywell V, Flacelière M, Elies P, Liaud P, Mazard T, Maucort-Boulch D, Tan W, Vire B, Villeneuve L, Ychou M, Kohli M, Joubert D, Prieur A., Free PMC Article | 10/3/2020 |
| fine-needle aspirate-ProGRP measurement could be served as an ancillary method for the differential diagnosis between medullary thyroid carcinoma (MTC) and non-MTC thyroid nodules | ProGRP AS A NOVEL BIOMARKER FOR THE DIFFERENTIAL DIAGNOSIS OF MEDULLARY THYROID CARCINOMA IN PATIENTS WITH THYROID NODULES.
Liang X, Zhu J, Cai M, Dai Z, Fang L, Chen H, Yu L, Lin Y, Lin E, Wu G. | 08/1/2020 |
| ProGRP may be useful as a potential biomarker for gastric cancer diagnosis and therapy. | Increased Progastrin-Releasing Peptide Expression is Associated with Progression in Gastric Cancer Patients.
Li L, Yin X, Meng H, Hu J, Yu Z, Xu J., Free PMC Article | 03/21/2020 |
| Studied association of progastrin-releasing peptide (proGRP), neuron specific enolase (NSE), chromogranin a (CgA), and squamous cell cancer antigen (SCCA1) in pulmonary neuroendocrine tumor (PNET) and non-small-cell lung carcinoma (NSCLC). Results showed ProGRP can distinguish PNET patients from NSCLC patients, and with adjusted NSE values, it can differentiate the PNET group from the benign disease group. | Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors.
Tutar N, Yetkin NA, Yazıcı C, Önal Ö, Kontaş O, Keleştemur F., Free PMC Article | 02/22/2020 |
| Serum ProGRP levels were elevated in half of the patients with Ewing sarcoma family of tumors and reflected therapeutic response. ProGRP is a reliable tumor marker for the diagnosis of Ewing sarcoma family of tumors. | Pro-gastrin-releasing peptide as a marker for the Ewing sarcoma family of tumors.
Honda Y, Katagiri H, Takahashi M, Murata H, Wasa J, Hosaka S, Ishida Y, Ito I, Muramatsu K, Mochizuki T, Matsuyama Y, Yamaguchi K. | 01/11/2020 |
| ProGRP and NSE serum expression levels predict therapeutic drug response in Chinese lung cancer patients. | Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
Wu XY, Hu YB, Li HJ, Wan B, Zhang CX, Zhang B, Hu H, Zhang Q, Lv TF, Zhan P, Song Y., Free PMC Article | 11/2/2019 |
| The serum pro-gastrin-releasing peptide (ProGRP) levels were increased in a variety of benign and malignant diseases and were considered a putative marker for small cell lung cancer (SCLC). | Clinical Application of Pro-Gastrin-Releasing Peptide.
Fang L, Huang Z, Lin Y, Fu J, Liang X, Liu F. | 10/19/2019 |
| There was no significant difference in the levels of pro-gastrin-releasing peptide (ProGRP) between males and females, but the serum ProGRP levels were positively correlated with age. | Age and Gender-Specific Reference Intervals for ProGRP in Healthy Chinese Han Ethnic Adults using the Roche Cobas Immunoassay.
Zhu Y, Yuan Y, Yang X, Lu Q, Lu X, Huang H. | 09/21/2019 |
| A panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC. | Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET, Koksal D, Aksu F, Dikmen ZG, Icen D, Maden E, Onder S, Akbiyik F, Emri S. | 09/1/2018 |
| Pro-GRP is sensitive for SCLC diagnosis. Since high marker levels are related to high disease burden, pro-GRP may have a negative prognostic significance. Follow-up studies are required to define its role in clinical practice in monitoring responses to treatment and early relapses | Clinical implications for pro-GRP in small cell lung cancer. A single center experience.
Cavalieri S, Morelli D, Martinetti A, Galli G, Nichetti F, de Braud F, Platania M. | 09/1/2018 |
| Altogether, these data show that humanized anti-progastrin antibodies might represent a potential new treatment for K-RAS-mutated colorectal patients, for which there is a crucial unmet medical need | Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.
Prieur A, Cappellini M, Habif G, Lefranc MP, Mazard T, Morency E, Pascussi JM, Flacelière M, Cahuzac N, Vire B, Dubuc B, Durochat A, Liaud P, Ollier J, Pfeiffer C, Poupeau S, Saywell V, Planque C, Assenat E, Bibeau F, Bourgaux JF, Pujol P, Sézeur A, Ychou M, Joubert D. | 06/23/2018 |
| Both TRPV1 and GRP are implied in midbrain physiology of importance to neurological and neuropsychiatric disorders. | Midbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease.
Viereckel T, Dumas S, Smith-Anttila CJ, Vlcek B, Bimpisidis Z, Lagerström MC, Konradsson-Geuken Å, Wallén-Mackenzie Å., Free PMC Article | 04/21/2018 |
| GRP/GRP-R signaling activation contributes to castration-resistant prostate cancer progression | Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.
Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R., Free PMC Article | 04/7/2018 |
| progastrin expression may be predictive of aggressive tumour behaviour in patients with colorectal cancer. | Progastrin: a potential predictive marker of liver metastasis in colorectal cancer.
Westwood DA, Patel O, Christophi C, Shulkes A, Baldwin GS. | 04/7/2018 |
| Thus the combination of favourable in vitro and in vivo properties renders BA1 as more potential antagonist bombesin-peptide for targeting GRP-receptor positive tumor. These properties are encouraging to carry out further experiments for non-invasive receptor targeting potential diagnostinc and therapeutic agent for tumors. | Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor.
De K, Banerjee I, Sinha S, Ganguly S. | 12/2/2017 |
| serum level not a biomarker in small cell lung cancer | The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X, Zhang W, Yin W, Xiao Y, Zhou C, Hu Y, Geng S., Free PMC Article | 12/2/2017 |
| pro-gastrin releasing peptide has a role in promoting the cell proliferation and progression in small cell lung cancer | Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer.
Gong Z, Lu R, Xie S, Jiang M, Liu K, Xiao R, Shen J, Wang Y, Guo L. | 06/10/2017 |
| Our results suggest that, similar to what happens in neutrophils, gastrin-releasing peptide is a migratory, rather than a proliferative, stimulus, for non-small cell lung carcinoma cells, indicating a putative role for gastrin-releasing peptide and gastrin-releasing peptide receptor in metastasis | Neuropeptide gastrin-releasing peptide induces PI3K/reactive oxygen species-dependent migration in lung adenocarcinoma cells.
Jaeger N, Czepielewski RS, Bagatini M, Porto BN, Bonorino C. | 04/8/2017 |
| Serum Pro-GRP was promising biomarker for SCLC diagnosis. | Serum pro-gastrin-releasing peptide in diagnosis of small cell lung cancer: A meta-analysis.
Wang H, Qian J. | 03/18/2017 |